Search Results 11-20 of 16883 for Adenocarcinoma, Non-Small Cell, Lung Cancer, Stage IV

1. Synergy with Grid Therapy and Immune Checkpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

   Participation eligibility · Age ≥ 18 years. · ECOG 0-2. · Stage IV non-small cell lung cancer progressing on standard of care first line immunotherapy or ...

2. Erlotinib with or without Bevacizumab in Treating Patients with Stage IV Non-Small Cell Lung Cancer with EGFR Mutations - Mayo Clinic

   ... Stage IV Non-Small Cell Lung Cancer with EGFR Mutations ... lung carcinoma, non ... Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas ...

3. A Study to Evaluate Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol) - Mayo Clinic

   ... stage IV ALK positive non-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth ...

4. A Study of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment for Patients with Stage IIIB/IV Non-Small Cell Lung Cancer - Mayo Clinic

   ... stage IIIB/IV adenocarcinoma non-small cell lung cancer that has epidermal growth factor receptor (EGFR) activating mutations. This study will also assess ...

5. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

   ... stage IV non-small cell lung cancer. Erlotinib ... Cytologically or histologically confirmed non-small cell lung carcinoma (NSCLC) ... cell type; if small cell ...

6. Advances in lung cancer immunotherapy and management of immune-mediated adverse events - Mayo Clinic

   Monotherapy, using the anti-PD-1 antibody pembrolizumab, is now Food and Drug Administration (FDA) approved for patients with stage IV non-small cell lung ...

7. Ruxolitinib in Combination with Pemetrexed/Cisplatin in Non Small Cell Lung Cancer - Mayo Clinic

   ... non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent. Participation eligibility. Participant eligibility includes age, gender, type ...

8. Clinical trials - Lung Cancer Program

   The purpose of this research trail is to study the genetic alteration/mutation and immune profiling in surgical resected Non-small Cell Lung Cancer (NSCLC) ...

9. Study of Pembrolizumab With Ipilimumab or Placebo in Participants with Untreated Metastatic Non-small Cell Lung Cancer - Mayo Clinic

   ... non-small cell lung cancer (NSCLC). The primary ... Have a histologically or cytologically confirmed diagnosis of Stage IV metastatic NSCLC (AJCC version 8).

10. Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study - Mayo Clinic

    Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study.